Neurophet뉴로핏

Neurophet's shares have fallen sharply over the past year while losses remain very large relative to its small revenue.

Neurophet is a KOSDAQ-listed software company making AI brain imaging tools for Alzheimer's and other neurodegenerative diseases, sold to hospitals, screening centers and drug trial sponsors. On the latest filed figures for the twelve months to H1 2026, revenue was about ₩2.6B against an operating loss of about ₩19.6B, and the share price closed at ₩6,540, down 68.1% over one year. The data does not include any analyst ratings or forecasts.

What stands out

• Trailing revenue is about ₩2.6B, while operating loss is about ₩19.6B and net loss about ₩23.0B, giving an operating margin of roughly -758%.
• Free cash flow was about -₩18.2B and borrowings of about ₩6.2B exceed cash of about ₩3.8B, so the company relies on funding beyond its operations.
• The 2025 annual figures show a similar pattern, with revenue of about ₩2.6B and an operating loss of about ₩16.5B.
• Filings in 2026 include convertible bond and convertible preferred share issuances, which can dilute existing shareholders.
• The share price is far below its 52-week high of ₩36,700, and the company's own discounted cash flow model gives a base value of ₩2,579 per share, below the current price.
• Foreign ownership fell from 6.8% to 5.7% over about 60 days, while retail investors were net buyers over the last 20 days.

What to watch

• The next quarterly and annual results, to see whether revenue growth can narrow the large operating loss.
• Any further share issuances, convertible bond conversions or financing needs, given the negative free cash flow and debt levels.
• Progress on overseas expansion in Japan, China and the United States, and new contracts such as the June 2026 major sales agreement; the data does not give details of its size or terms.